Patrick Starlinger

Prof. Dr. Patrick Starlinger

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Hepatology
Verified
Journal Article
Closed access
PDF file
PSPatrick Starlinger
Patrick Starlinger
AAAlice Assinger
Alice Assinger
SHStefanie Haegele
Stefanie Haegele
DWDavid Wanek
David Wanek
SZSilvia Zikeli
Silvia Zikeli
TGThomas Gruenberger
Thomas Gruenberger

22 March 2024 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
DFDavide Ferrari
Davide Ferrari
TVTommaso Violante
Tommaso Violante
MNMarco Novelli
Marco Novelli
PSPatrick Starlinger
Patrick Starlinger
RSRory L. Smoot
Rory L. Smoot
DLDavid W. Larson
David W. Larson

3 November 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
PSPatrick Starlinger
Patrick Starlinger
SHStefanie Haegele
Stefanie Haegele
FOFlorian Offensperger
Florian Offensperger
LOLukas Oehlberger
Lukas Oehlberger
DPDavid Pereyra
David Pereyra
Alice AssingerAlice Assinger
Alice Assinger
Platelets promote liver regeneration through site‐specific serotonin release from dense granules, triggering proliferative signaling in hepatocytes. However, the effects of factors derived from platelet α‐granules on liver regeneration are unclear, because α‐granules contain bioactive molecules with opposing functions. Because α‐granule molecules are stored in separate compartments, it has been suggested that platelets selectively release their α‐granule content dependent on the environmental stimulus. Therefore, we investigated the pattern of circulating α‐granule molecules during liver regeneration in 157 patients undergoing partial hepatectomy. We measured plasma levels of α‐granule‐derived factors in the liver vein at the end of liver resection, as well as on the first postoperative day. We observed a rapid accumulation of platelets within the liver after induction of liver regeneration. Platelet count and P‐selectin (a ubiquitous cargo of α‐granules) were not associated with postoperative liver dysfunction. However, low plasma levels of vascular endothelial growth factor (VEGF), but high levels of thrombospondin 1 (TSP‐1), predicted liver dysfunction after resection. Patients with an unfavorable postoperative α‐granule release profile (high TSP‐1/low VEGF) showed substantially worse postoperative clinical outcomes. The unfavorable postoperative α‐granule release profile was associated with increased postoperative portal venous pressure and von Willebrand factor antigen levels as a marker for intrahepatic endothelial dysfunction. Conclusion: The postoperative profile of circulating platelet‐derived factors correlates with the ability of the remnant liver to regenerate. Portal venous pressure and intrahepatic endothelial dysfunction might account for the selective granule release profile. Selective modulation of platelet α‐granule release in patients may represent an attractive target for therapeutic interventions to improve liver regeneration and clinical outcomes after partial hepatectomy. (Hepatology 2016;63:1675‐1688)

8 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Marion MussbacherMarion Mussbacher
Marion Mussbacher
WSWaltraud C. Schrottmaier
Waltraud C. Schrottmaier
Manuel SalzmannManuel Salzmann
Manuel Salzmann
CBChristine Brostjan
Christine Brostjan
JSJohannes A Schmid
Johannes A Schmid
AAAlice Assinger
Alice Assinger
Platelets store a plethora of different molecules within their granules, modulating numerous pathways, not only in coagulation, but also in angiogenesis, wound healing, and inflammatory diseases. These molecules get rapidly released upon activation and therefore represent an easily accessible indirect marker for platelet activation. Accurate analysis of platelet-derived molecules in the plasma requires appropriate anticoagulation to avoid in vitro activation and subsequent degranulation of platelets, potentially causing artificially high levels and masking biologically relevant differences within translational research studies. However, there is still enormous heterogeneity among anticoagulants used to prevent unwanted platelet activation, so that plasma levels reported for platelet granule contents range over several orders of magnitude. To address this problem and to define the most robust method of plasma preparation to avoid in vitro platelet activation during processing, we compared plasma concentrations of the three platelet-stored factors thrombospondin (TSP-1), platelet factor 4 (PF4), and soluble P-selectin (sCD62P) between human blood samples anticoagulated with either citrate-theophylline-adenosine-dipyridamole (CTAD), acid-citrate-dextrose (ACD), citrate, ethylenediaminetetraacetic acid (EDTA) or heparin. Additionally, we assessed the effect of storage temperature and time between blood drawing and sample processing within the differentially anticoagulated samples. Our data strongly support the use of CTAD as anticoagulant for determining plasma concentrations of platelet-stored molecules, as anticoagulation with heparin or EDTA led to a 12.4- or 8.3-fold increase in plasma levels of PF4, respectively. Whereas ACD was similar effective as CTAD, citrate only showed comparable PF4 plasma levels when plasma was kept at 4°C. Moreover, blood sampling with CTAD as anticoagulant resulted in the most reproducible values, even when samples were processed at ambient temperature or after storage over 6 hours. In the latter case, anticoagulation with heparin or EDTA led to artificially high plasma levels indicative of in vitro platelet activation. Therefore, we want to raise scientific awareness for choosing CTAD as optimal anticoagulant for the detection of platelet-stored molecules in plasma.

28 April 2025 in Cancer Discovery
Verified
Journal Article
Closed access
STSheue-Fen Tzeng
Sheue-Fen Tzeng
YYYi-Ru Yu
Yi-Ru Yu
JPJaeoh Park
Jaeoh Park
JRJanusz von Renesse
Janusz von Renesse
HHHuey-Wen Hsiao
Huey-Wen Hsiao
PHPing-Chih Ho
Ping-Chih Ho
Tumor cells develop various strategies to evade immune surveillance, one of which involves altering the metabolic state of the tumor microenvironment. In response to metabolic stress in the tumor microenvironment, several tumor-infiltrating immune subsets upregulate CD36 to take up lipids. This leads to impaired antitumor immunity, as intratumoral regulatory T cells exhibit increased survival and suppressive activity, whereas CD8+ T cells become more susceptible to ferroptosis and exhaustion. In this study, we develop a humanized anti-CD36 IgG4 antibody, PLT012, against the lipid-binding domain of CD36 with excellent safety and favorable pharmacokinetic features in mice and cynomolgus monkeys. PLT012 alone or in combination with PD-L1 blockade or standard-of-care immunotherapy results in robust antitumor immunity in both immunotherapy-sensitive and -resistant hepatocellular carcinomas (HCC). Notably, PLT012 also reprograms the immune landscape of human HCC ex vivo. Our findings provide proof-of-concept evidence that PLT012 reprograms antitumor immunity in HCC, positioning it as a first-in-class immunotherapy targeting CD36. Significance: Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.

3 August 2010 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PSPatrick Starlinger
Patrick Starlinger
HMHerwig P. Moll
Herwig P. Moll
AAA. Assinger
A. Assinger
CNC. Nemeth
C. Nemeth
KHKonrad Hötzenecker
Konrad Hötzenecker
CBChristine Brostjan
Christine Brostjan